Search

Your search keyword '"Lowes, Brian"' showing total 6 results
Start Over Author "Lowes, Brian" Journal circulation: heart failure
6 results on '"Lowes, Brian"'

1. Validating an Idiopathic Dilated Cardiomyopathy Diagnosis Using Cardiovascular Magnetic Resonance: The Dilated Cardiomyopathy Precision Medicine Study

Author

Haas, Garrie J., primary, Zareba, Karolina M., additional, Ni, Hanyu, additional, Bello-Pardo, Erika, additional, Huggins, Gordon S., additional, Hershberger, Ray E., additional, Kinnamon, Daniel D., additional, Jordan, Elizabeth, additional, Haas, Garrie J., additional, Fishbein, Daniel P., additional, Gottlieb, Stephen S., additional, Wheeler, Matthew T., additional, Hofmeyer, Mark, additional, Tang, W.H. Wilson, additional, Owens, Anjali T., additional, Moore, Charles K., additional, Jimenez, Javier, additional, Trachtenberg, Barry H., additional, Sweitzer, Nancy K., additional, Shah, Palak, additional, Lowes, Brian D., additional, Stoller, Douglas, additional, Smart, Frank, additional, Morris, Alanna A., additional, Wilcox, Jane E., additional, Katz, Stuart, additional, Pan, Stephen, additional, Ewald, Gregory A., additional, Aaronson, Keith D., additional, Wang, Jessica J., additional, Pamboukian, Salpy, additional, Judge, Daniel P., additional, Kransdorf, Evan P., additional, Garg, Sonia, additional, Desvigne-Nickens, Patrice, additional, Troendle, James, additional, Fu, Yi-Ping, additional, and Hindorff, Lucia, additional

Published
2022
Full Text
View/download PDF

3. An α 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the β-Blocker Bucindolol in Chronic Heart Failure

Author

Bristow, Michael R., primary, Murphy, Guinevere A., additional, Krause-Steinrauf, Heidi, additional, Anderson, Jeffrey L., additional, Carlquist, John F., additional, Thaneemit-Chen, Surai, additional, Krishnan, Vaishali, additional, Abraham, William T., additional, Lowes, Brian D., additional, Port, J. David, additional, Davis, Gordon W., additional, Lazzeroni, Laura C., additional, Robertson, Alastair D., additional, Lavori, Phillip W., additional, and Liggett, Stephen B., additional

Published
2010
Full Text
View/download PDF

5. An α2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the β-Blocker Bucindolol in Chronic Heart Failure.

Author

Bristow, Michael R., Murphy, Guinevere A., Krause-Steinrauf, Heidi, Anderson, Jeffrey L., Cariquist, John F., Thaneemit-Chen, Surai, Krishnan, Vaishali, Abraham, William T., Lowes, Brian D., Port, J. David, Davis, Gordon W., Lazzeroni, Laura C., Robertson, Alastair D., Lavori, Phillip W., and Stephen B. Liggett

Subjects
HEART failure, ALPHA adrenoceptors, BETA adrenoceptors, ADRENERGIC beta blockers, SYMPATHOLYTIC agents, GENETIC polymorphisms, GENETICS
Abstract

The article focuses on a study which investigated whether alpha-2C-adrenergic receptor (AR) polymorphisms affect sympatholytic effects of bucindolol in patients with chronic heart failure. Outcomes of chronic heart failure were determined by adrenergic activation. The study concluded that alpha-2Creceptor genotype influenced the Beta-Blocker Evaluation of Survival Trial AR polymorphism substudy, the norepinephrine lowering and clinical therapeutic responses to bucindolol.

Published
2010
Full Text
View/download PDF

6. An 2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the -Blocker Bucindolol in Chronic Heart Failure

Author

Bristow, Michael R., Murphy, Guinevere A., Krause-Steinrauf, Heidi, Anderson, Jeffrey L., Carlquist, John F., Thaneemit-Chen, Surai, Krishnan, Vaishali, Abraham, William T., Lowes, Brian D., Port, J David, Davis, Gordon W., Lazzeroni, Laura C., Robertson, Alastair D., Lavori, Phillip W., and Liggett, Stephen B.

Abstract

Adrenergic activation is an important determinant of outcomes in chronic heart failure. Adrenergic activity is regulated in part by prejunctional 2C-adrenergic receptors (ARs), which exhibit genetic variation in humans. Bucindolol is a novel -AR blocking agent that also lowers systemic norepinephrine and thus is also a sympatholytic agent. This study investigated whether 2C-AR polymorphisms affect sympatholytic effects of bucindolol in patients with heart failure.

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results